All News

The results of the study show the importance of considering neighborhood-level disparities to address and improve medication adherence, according to investigators.

The study authors note that the findings could be significant in future HIV vaccine design and development, as well as new approaches to HIV immunotherapy.

The results found that INT301 met both its primary and secondary endpoints and could be a safe and effective option for individuals that experience food allergies.

Individuals received 4 daily short messages that reminding them to participate in self-care, active engagement, and early intervention for the first 30 days of the study.

Investigators aim to find a substitution for incomplete Freund adjuvant, which is not suitable for use in humans but shows a strong response to antigen-specific systemic immune responses.

Investigators will evaluate prophylactic tocilizumab prior to treatment with teclistamab.

Preclinical data showed that LP-184 shrunk tumors in vivo by more than 90% in just 8 weeks.

The results support perioperative nivolumab as a potential new treatment option.

Language gaps resulted in barriers and underdiagnosing in children with common allergies, limiting support for these patients and their families.

The CMS FAQ ruling is resulting in barriers to care for patients.

This approval makes birch triterpenes the first treatment for wounds associated with junctional epidermolysis bullosa to be approved by the FDA.

If approved, V116 would offer significant improvements in safety and effectiveness for the prevention of pneumococcal disease.

Amiodarone also provides pan-variant protection against toxins, a potentially growing area of research in C. difficile infection treatment.

The study authors note that interventions to reverse frailty, such as screening and assessments to identify issues, can help in the management of COPD and asthma and lead to better prognoses.

Previously, garadacimab was granted an orphan drug designation as a therapy for hereditary angioedema by both the FDA and EMA.

Less than 1% of individuals developed Clostridioides difficile infection (CDI), but for those who previously had a CDI the year before, 12% developed a new infection.

The antibody response among those that interrupted treatment was doubled at 4 weeks and 1.5 times greater at 26 weeks.

Treatment options can be limited for this patient population.

Rosemary Sassic-Mihalko, PharmD, is the fourth owner and first female owner of pittsburgh’s oldest pharmacy

Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, discusses the dynamic landscape of the biosimilars market, providing key insights into its current status and future projections.

Using information from clinical studies and her experiences working in the field, Stephanie Kirk describes treatment options that are on the horizon, and how removing stigma is key in HIV care.

There is a prognostic impact of clinical and immunohistochemistry markers.

In the study, a new policy empowered unit-based pharmacists to evaluate the patient’s needs and, when safe, switch from a PPI to an H2 blocker.

The most recent advances included an approved vaccine that could immunize both the elderly and pregnant women, along with the release of nirsevimab.

The approval marks the first for an alternative to platinum-containing chemotherapy.

Older individuals and individuals that experienced severe COVID-19 are at high risk of increased cardiac disturbances.

Unsuccessful arguments at trial court level are upheld on appeal

Investigators analyzed the effects of harmful accumulation of HDAC6 in the brains of mouse models with Alzheimer disease to determine any changes in disease progression.

The study, which consists of 3 trials, will continue with oral PrEP regimens; however, the vaccination trials have stopped due to the unlikely chance of the vaccine showing efficacy.

Although treatment is effective, AEs remain difficult for patients.